knee osteoarthritis News
-
A new study confirming correlation between Biomechanical Markers and clinical outcomes in knee OA patients
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of knee OA ...
By Emovi
-
Gelexir becomes Gelmetix
We are proud to announce that our rebranding process is now complete. Gelexir Healthcare, known for being a spin off of the University of Manchester and for its cutting edge R&D work on non-invasive treatments for Chronic Low Pain, officially becomes Gelmetix. This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: ...
-
Gelmetix signs collaboration for development of Knee Osteoarthritis product
Stemmatters and Gelmetix have established an agreement to develop an innovative hydrogel based device for the treatment of cartilage lesions. The partnership established focuses on the pre-clinical development of the new device towards clinical studies in human patients and subsequent market authorization. The new medical device aims to ensure a significant advance in the treatment of ...
-
Kinestique Diagnostic Centre Integrates New Technology that Accurately and Objectively Addresses Knee Pain, The First in Singapore, Asia
Kinestique Diagnostic Centre announces today the launch of the KneeKGTM in their inaugural clinic, the firsts in the country and Southeast Asia. Developed by Emovi, the KneeKGTM is to the knee, what an EKG is for the heart, and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee ...
By Emovi
-
16 Mar Moximed Closes Oversubscribed $50MM Financing Round
Hayward, CA, USA, March 15, 2017 – Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex ...
By Moximed Inc
-
FYZICAL Therapy and Balance Centers El Paso Brings New Technology to its Clinics to Support Patients Faced With Knee Pain
FYZICAL Therapy and Balance Centers – El Paso, announces today the launch of KneeKGTM into all four of their locations. Developed by Emovi, the KneeKG is for the knee, like an EKG is for the heart and provides valuable data that enables physicians and other healthcare professionals to determine the most appropriate patient-specific care plan to restore optimal knee function. Knee pain is ...
By Emovi
-
Emovi, Inc. Announces Partnership with Sports Illustrated as Key Sponsor for The Sports Illustrated Awards
Emovi, Inc., a global medical device developer, today announced a partnership with Sports Illustrated as a sponsor of the 2020 Sports Illustrated Awards (SI Awards) The SI Awards will take place in Las Vegas on December 19. Viewers can stream the primetime broadcast live via the Sports Illustrated Facebook page beginning at 7:00 PM ET . The award ceremony will feature special presentations, ...
By Emovi
-
Intecore Physical Therapy the First and ONLY PT Clinic in the Western US to Integrate KneeKG into Clinics
Outpatient orthopedic and sports medicine rehabilitation provider, Intecore Physical Therapy, broadens its care and support for patients experiencing knee pain with the addition of the KneeKG™ System into all of their clinics. Developed by Emovi, the KneeKG™ is used on the knee, like an EKG is for the heart, by providing valuable data that enables the Physical Therapy team to ...
By Emovi
-
Emovi Partners Pairs up With Olympic Gold Medalist Bruny Surin to Launch the New Emovi’s Athlete Support Program
The new program is designed for Canadian athletes to improve explosiveness, endurance, control, and stability as they prepare to compete on the world stage Emovi, Inc. announces the launch of its new program for Canadian athletes in collaboration with Gold Medal Olympian Bruny Surin. The Athlete Support Program invites athletes to integrate Emovi’s flagship device, the KneeKGTM, into their ...
By Emovi
-
The American Academy of Orthopedic Surgeons has just recognized that when integrated in patient education, Knee Kinesiography with the KneeKG system provides statistically significant and clinically superior improvements compared to the results obtained w
Emovi inc. is pleased to announce that Geisinger Health, comprised of nine hospital campuses, two research centers, a college of medicine, and a 550,000-member health plan serving more than three million residents in central, south-central, and northeast Pennsylvania, broadens its care and support for patients experiencing knee pain with the addition of five KneeKG Systems into their clinics. ...
By Emovi
-
World’s First “Artificial Meniscus” Available in Israel
Active Implants LLC, a company that develops orthopedic implant solutions, today announced that two patients in Israel have undergone knee surgery for the company’s NUsurface® Meniscus Implant – the first “artificial meniscus” to be marketed in the Middle East. Until now, the NUsurface Implant was only available in Israel in clinical trials. The procedures were ...
-
Sun Pharma & Moebius Medical Sign Exclusive Global Licensing Deal to Develop Novel Liposomal Non-opioid Pain Product for Osteoarthritis
Clinical data showed superior efficacy & similar safety of MM-II vs. standard of care (hyaluronic acid) for treatment of pain in osteoarthritis Sun Pharma to fund further development of MM-II including completion of Phase 2 and Phase 3 clinical programs and any required preclinical work necessary for regulatory approval Sun Pharma has worldwide commercialization & manufacturing rights ...
-
Moebius Medical Announces Dosing of First Patient in Global Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain ...
-
KiOmed Pharma reports promising long-term results in a new European multi centric survey Treatment of Advanced Knee OsteoArthritis
KiOmed Pharma, an innovative Belgian biotech company, has reported positive safety and efficacy outcomes following the treatment of nearly 80 patients suffering from Knee OsteoArthritis (OA). This European Healthcare Professional (HCP) survey yielded a global long-term improvement of OA symptoms and shows preliminary evidence of improved outcomes in patients with advanced stage OA. ‘This ...
-
Moebius Medical Announces FDA Clearance of IND Application for Phase IIb Clinical Trial of MM-II, a Novel Treatment for Knee Osteoarthritis Pain
Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022 Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Investigational New Drug (IND) application to ...
-
KiOmed Pharma and moveUP Partner to Develop and Market a Companion Healthcare Application for Personalised Treatment of Osteoarthritis
Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, while exclusive ...
-
A Brand New Collaboration Between Emovi and The Geneva Foundation
In partnership with The Geneva Foundation and supporting grant from the Quebec Ministry of Economy and Innovation, Emovi will launch the 24-month clinical project within US Army clinics at Fort Bragg and High Point University, North Carolina, USA Emovi, Inc., a leading medical device developer and manufacturer for orthopaedics, announced today a clinical collaboration with the US Army in ...
By Emovi
-
Active Implants’ NUsurface Meniscus Implant Provides Statistically Superior Pain Relief
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the company’s NUsurface® Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy. The results were presented at the American Orthopedic Society for Sports ...
-
Cytex Founding Scientists Receive Top Award in Orthopaedic Research
The American Academy of Orthopedic Surgeons (AAOS) today announced that the 2021 Kappa Delta Elizabeth Winston Lanier Award has been granted to Cytex Therapeutics founders Drs. Farshid Guilak, Bradley Estes and Frank Moutos. The Kappa Delta Awards recognize research in musculoskeletal disease or injury with potential to advance patient care and are the highest awards in the field of orthopaedic ...
-
First tahoe unicompartmental knee system (TUKS) procedure
El Dorado Hills, CA, June 2022 – Shalby Advanced Technologies, (DBA Consensus Orthopedics) proudly reports its first implantation of The Tahoe Uni-compartmental Knee System (TUKS), in Plano,Texas on June 2, 2022. The surgery was performed by Dr. Richard Reitman and was a great surgical success. This surgery marks the culmination of over 6 years of research and development. The patient, a 52 ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you